Drug intelligence / Profile preview

Larkspur Biosciences TIM-1 inhibitor

Development stage: Preclinical
Lead developer: Larkspur Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

The TIM-1 program is a preclinical-stage cancer therapeutic being developed by Larkspur Biosciences in collaboration with Alloy Therapeutics through their joint venture, Tiburon Therapeutics. The program focuses on inhibiting T-cell immunoglobulin and mucin domain-containing protein 1 (TIM-1), a checkpoint protein identified on B cells that plays a critical role in suppressing antitumor immunity. Based on foundational research by Larkspur founder Vijay Kuchroo, the therapy aims to block TIM-1 signaling to restore B-cell-mediated immune activation against tumors. The program is currently in the lead discovery phase for the treatment of various cancers.

Other names: Tiburon TIM-1 program

Targets

TIM-1 (T-cell immunoglobulin and mucin domain-containing protein 1)

Beyond the preview

Go deeper on Larkspur Biosciences TIM-1 inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Larkspur Biosciences TIM-1 inhibitor.

Explore the full profile